In CAR T cells, a modified form of PGC-1α, stimulated mitochondrial biogenesis and metabolically reprogrammed CAR T cells, resulting in improved anti-tumor efficacy in solid tumors (303). This evidence concerns the gene PPARGC1A and neoplasm.